Activates GLP-1 and GIP receptors to enhance insulin secretion when needed, reduce liver glucose production, and slow gastric emptying, lowering blood sugar and HbA1c levels.
Administration: Inject once weekly, any time of day, with or without food. If a dose is missed, take it within 4 days; otherwise, skip and resume the regular schedule. Rotate injection sites to prevent irritation.
Efficacy: Clinical trials show 75–90% of patients on Mounjaro (across doses) achieve HbA1c <7%, with significant fasting glucose reductions (e.g., ~40–58 mg/dL at 5 mg; higher doses like 12.5 mg typically yield greater reductions). Weight loss (12–25 lbs or more across doses) is common but not FDA-approved for this purpose; Zepbound (same active ingredient) is approved for weight loss
